Justices Urged To Bar Passive Infringement For Skinny Labels

By Dani Kass · February 19, 2026, 9:04 PM EST

The Federal Circuit cleared the path for branded-drug makers to claim a rival induced infringement of a patent without taking any active steps to do so, Hikma told the U.S. Supreme...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

Hikma Pharmaceuticals USA Inc., et al., Petitioners v. Amarin Pharma, Inc., et al.

Case Number

Court

Supreme Court

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

February 19, 2025

Recent Articles By Dani

February 10, 2026
Apple Again Pushes To Escape Masimo's $634M IP Verdict
February 02, 2026
Split Fed. Circ. Won't Revive Massager Design Patent Case
December 18, 2025
ITC Clears Toy Gun Imports, Will Review Smart Rings, Vapes
December 02, 2025
Squires Institutes First PTAB Challenges Since Taking Over
October 08, 2025
Del. Judge May Have Mallinckrodt Choose: Injunction Or $10M
October 06, 2025
Fed. Circ. Vacates J&J's $20M Loss Over Patent Ownership
September 05, 2025
Stewart Tackles Markets, Injunctions In Newest PTAB Reviews
August 05, 2025
Stewart Won't Reconsider Her 1st Settled Expectations Denial
July 28, 2025
PREP Act Won't Save COVID Test Manufacturer From IP Suit
July 11, 2025
Fed. Circ. Questions Patent Ownership After J&J's $20M Loss